Log in

Altimmune Stock Forecast, Price & News

+0.32 (+2.74 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $12.00
50-Day Range N/A
52-Week Range
Now: $12.00
Volume540,811 shs
Average Volume1.90 million shs
Market Capitalization$394.92 million
P/E RatioN/A
Dividend YieldN/A
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALT



Sales & Book Value

Annual Sales$5.80 million
Book Value$2.97 per share


Net Income$-20,520,000.00
Net Margins-858.94%


Market Cap$394.92 million
Next Earnings Date11/11/2020 (Estimated)
+0.32 (+2.74 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Altimmune (NASDAQ:ALT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Altimmune?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Altimmune

When is Altimmune's next earnings date?

Altimmune is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Altimmune

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.65. The company earned $0.72 million during the quarter, compared to analysts' expectations of $1 million. Altimmune had a negative return on equity of 50.83% and a negative net margin of 858.94%.
View Altimmune's earnings history

What price target have analysts set for ALT?

2 analysts have issued 1 year target prices for Altimmune's stock. Their forecasts range from $31.00 to $31.00. On average, they expect Altimmune's stock price to reach $31.00 in the next year. This suggests a possible upside of 158.3% from the stock's current price.
View analysts' price targets for Altimmune

Are investors shorting Altimmune?

Altimmune saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 2,080,000 shares, an increase of 41.5% from the September 15th total of 1,470,000 shares. Based on an average daily volume of 2,540,000 shares, the short-interest ratio is currently 0.8 days.
View Altimmune's Short Interest

Who are some of Altimmune's key competitors?

What other stocks do shareholders of Altimmune own?

Who are Altimmune's key executives?

Altimmune's management team includes the following people:
  • Dr. Vipin K. Garg, Pres, CEO & Director (Age 62, Pay $566.63k)
  • Mr. William Michael Brown, CFO & Principal Accounting Officer (Age 38, Pay $443.16k)
  • Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF, Chief Medical Officer (Age 67, Pay $371.29k)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer
  • Dr. M. Scot Roberts, Chief Scientific Officer (Age 61)
  • Mr. José Ochoa, Chief Bus. Officer

What is Altimmune's stock symbol?

Altimmune trades on the NASDAQ under the ticker symbol "ALT."

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $12.00.

How big of a company is Altimmune?

Altimmune has a market capitalization of $394.92 million and generates $5.80 million in revenue each year. The company earns $-20,520,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Altimmune employs 25 workers across the globe.

What is Altimmune's official website?

The official website for Altimmune is altimmune.com.

How can I contact Altimmune?

Altimmune's mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The company can be reached via phone at 240-654-1450 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.